Mayne buys back US Doryx rights from Actavis for $50mm
Executive Summary
Actavis PLC divested to Mayne Pharma Group Ltd. its US rights to the tetracycline antibiotic Doryx (delayed-release doxycycline) for severe acne. Mayne, which originally developed the drug, paid $50mm and also gets the product's trademark, marketing materials, inventory, and medical and technical data.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice